Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKI-G-801 in Relapsed or Refractory AML
NCT03564288Phase 1Completed
- Sponsor
- Oscotec Inc.
- Start
- Feb 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of denfivontinib in acute myeloid leukemia (AML), sponsored by Oscotec Inc. Primary endpoints: Recommended Phase 2 Dose up to 36 months, Overall Response Rate and 5 more. Started Feb 2018; status: completed.
02
Drugs
denfivontinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03564288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564288.